Who
Darren Charlton Smith
Group Chief Financial Officer
Company insider
Files Form 4 as: Group Chief Financial Officer, Telix Pharmaceuticals.
In numbers
- Trades disclosed
- 6
- Buys
- 1
- Sells
- 0
- Bought
- $40K
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 29 Mar 2026
- Last trade
- 7 Sep 2026
- Last filed
- 14 Sep 2026
Companies traded
Activity over time
1 Sep – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 7 Sep 2026filed 14 Sep 2026 | TLX Telix PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $20K2,071 at $9.66 | filing |
| 7 Sep 2026filed 14 Sep 2026 | TLX Telix PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $20K2,071 at $9.66 | filing |
| 29 Mar 2026filed 1 Apr 2026 | TLX Telix PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —1,111 at $0.00 | filing |
| 29 Mar 2026filed 1 Apr 2026 | TLX Telix Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,111 at $0.00 | filing |
| 29 Mar 2026filed 1 Apr 2026 | TLX Telix Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,111 at $0.00 | filing |
| 29 Mar 2026filed 1 Apr 2026 | TLX Telix PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —1,111 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.